Amgen/Cytokinetics Phase III Heart Failure Data Are Below Expectations
Omecamtiv Met Primary, Missed Key Secondary Endpoints
Executive Summary
Analysts considered the Phase III GALACTIC-HF study of omecamtiv mecarbil a failure but some anticipated that detailed data to be presented next month could at least partially redeem the drug.
You may also be interested in...
The (Non-COVID) Clinical Trial Hits And Misses Of 2020
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure
Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.
Need a specific report? 1000+ reports available
Buy Reports